(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
Public ClinicalTrials.gov record NCT04862780. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study Targeting Acquired Resistance Mechanisms in Patients With EGFR Mutant Non-Small Cell Lung Cancer
Study identification
- NCT ID
- NCT04862780
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Blueprint Medicines Corporation
- Industry
- Enrollment
- 177 participants
Conditions and interventions
Conditions
- Adenocarcinoma
- Antineoplastic Agents
- Bronchial Neoplasms
- Carcinoma
- Carcinoma, Bronchogenic
- Carcinoma, Non-Small-Cell Lung
- EGF-R Positive Non-Small Cell Lung Cancer
- EGFR Activating Mutation
- EGFR C797S
- EGFR Exon 19 Deletion
- EGFR Gene Mutation
- EGFR L858R
- EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance
- EGFR T790M
- Lung Diseases
- Lung Neoplasms
- Neoplasms
- Neoplasms by Histologic Type
- Neoplasms by Site
- Neoplasms, Nerve Tissue
- Protein Kinase Inhibitors
- Respiratory Tract Disease
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
Interventions
- BLU-945 Drug
- osimertinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 28, 2021
- Primary completion
- Oct 6, 2024
- Completion
- Oct 6, 2024
- Last update posted
- Feb 9, 2025
2021 – 2024
United States locations
- U.S. sites
- 10
- U.S. states
- 6
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UC San Diego Moores Cancer Center | La Jolla | California | 92093 | — |
| Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute | Los Angeles | California | 90048 | — |
| UC Irvine Health, Chao Family Comprehensive Cancer Center | Orange | California | 92868 | — |
| University of Colorado Hospital - Anschutz Cancer Pavilion (ACP) | Aurora | Colorado | 80045 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| NYU Langone Health, Laura and Isaac Perlmutter Cancer Center | New York | New York | 10016 | — |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04862780, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 9, 2025 · Synced May 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04862780 live on ClinicalTrials.gov.